Claims for Patent: 7,973,148

Summary for Patent: 7,973,148

Title:	Crustacean expression vector
Abstract:	Methods and constructs for genetic manipulation of one or more of shrimp, shellfish, mollusks, and fish are disclosed. The nucleic acid construct includes a promoter and an internal ribosome entry site of an insect picomavirus, such as a cricket paralysis-like picomavirus. One or more open reading frames can be operably associated with one or both of the promoter and the internal ribosome entry site, and one or more proteins or protein subunits can be expressed upon introduction of the construct into a host cell, such as into a shrimp. Method for producing immortalized crustacean cell lines using enhancer elements derived from shrimp and/or shrimp viruses are also described.
Inventor(s):	Dhar; Arun K. (Sykesville, MD), Allnutt; F. C. Thomas (Glenwood, MD)
Assignee:	Advanced Bionutrition Corporation (Columbia, MD)
Application Number:	11/587,770
Patent Claims:	1. A non-naturally-occurring nucleic acid construct for expressing at least one cistron in a crustacean cell, the construct comprising a virus promoter from a virus that infects shrimp and an insect picornavirus (IPV) internal ribosome entry site (IRES), wherein the promoter and the IRES are operably linked with the at least one cistron for expression of the cistron in the cell, wherein the promoter is selected from the group consisting of P2 and P61 of infectious hypodermal and hematopoietic necrosis virus(IHHNV). 2. The construct of claim 1, wherein the IRES is capable of infecting crustaceans from the phylum Arthropoda. 3. The construct of claim 1, wherein the IRES is the IRES of an 5'-untranslated region of the insect picornavirus. 4. The construct of claim 1, wherein the IRES is the IRES of an intergenic region of the insect picornavirus having at least two ORFs. 5. The construct of claim 1, wherein the IRES is a Taura syndrome virus (TSV) IRES. 6. The construct of claim 5, wherein the IRES is the IRES of the 5'-untranslated region of TSV. 7. The construct of claim 1, wherein the IRES is an IRES of an IPV that infects shrimp. 8. The construct of claim 1, wherein the construct further comprises an animal cell origin of replication site (ORS). 9. The construct of claim 8, wherein the animal is a crustacean. 10. The construct of claim 9, wherein the crustacean is a shrimp. 11. The construct of claim 10, wherein the shrimp is a Penaeus shrimp. 12. The construct of claim 1, wherein the cistron comprises a first open reading frame (ORF). 13. The construct of claim 12, wherein the ORF is not interrupted by an intron. 14. The construct of claim 12, wherein the ORF encodes a detectable marker. 15. The construct of claim 12, further comprising a second ORF operably associated with the IRES. 16. The construct of claim 15, wherein at least one of the first and second ORFs encodes a protein not normally expressed in a shrimp. 17. A method of expressing a protein in a crustacean cell, the method comprising introducing into the cell a non-naturally-occurring nucleic acid construct, the construct comprising a viral promoter from a virus that infects a crustacean and an IPV IRES, wherein an ORF encoding the protein is operably linked with the promoter and the IRES, and wherein the promoter is selected from the group consisting of P2 and P61 of infectious hypodermal and hematopoietic necrosis virus (IHHNV); and culturing the cell for expression of the protein. 18. The method of claim 17, wherein the protein is a eukaryotic protein. 19. The method of claim 17, wherein the protein is a shrimp protein. 20. The method of claim 17, wherein the crustacean is a shrimp. 21. The method of claim 20, wherein the shrimp is a Penaeus shrimp. 22. The method of claim 17, wherein the construct is a plasmid. 23. The method of claim 17, wherein the construct is introduced into the cell using a virus vector. 24. The method of claim 17, wherein the construct is introduced into the cell ballistically. 25. The method of claim 17, wherein the construct is introduced into the cell by electroporation. 26. The method of claim 17, wherein the protein is a protein that exerts a protective effect on the cell. 27. The method of claim 17, wherein the protein is a protein that exerts a protective effect on an animal that comprises the cell. 28. The method of claim 17, wherein the protein is a protein that exerts a therapeutic effect on the cell. 29. The method of claim 17, wherein the protein is a protein that exerts a therapeutic effect on an animal that comprises the cell. 30. The method of claim 17, wherein the protein is a protein that exerts a regulatory effect on expression of an endogenous gene of the cell. 31. A method of expressing a protein in a marine animal cell, the method comprising introducing into the cell a non-naturally-occurring nucleic acid construct, the construct comprising a viral promoter from a virus that infects shrimp and an insect picornavirus IPV internal ribosome entry site IRES, wherein an ORF encoding the protein is operably linked with the promoter and the IRES for expression of the protein in a marine animal cell, and wherein the promoter is selected from the group consisting of P2 and P61 of infectious hypodermal and hematopoietic necrosis virus (IHHNV), and culturing the cell for expression of the protein. 32. A non-naturally-occurring nucleic acid construct for expressing a cistron in a crustacean cell, the construct comprising a virus promoter from a virus that infects crustacean and an insect picornavirus (IPV) internal ribosome entry site (IRES), wherein at least the promoter is operably linked to the cistron, wherein the IRES is from a virus known to infect the crustacean, wherein the promoter is selected from the group consisting of P2 and P61 of infectious hypodermal and hematopoietic necrosis virus(IHHNV). 33. A non-naturally-occurring nucleic acid construct for expressing at least one cistron in a host cell, the construct comprising a virus promoter and an insect picornavirus (IPV) internal ribosome entry site (IRES), wherein the promoter and the IRES are operably linked with the cistron for expression of the cistron in the host cell, wherein the promoter is selected from the group consisting of p2 and p61 of infectious hypodermal and hematopoietic necrosis virus (IHHNV) and wherein the host cell is selected from a group consisting of bacteria, yeast, insect, fish, shellfish and mollusk. 34. The construct of claim 33, wherein the IRES is the IRES of the 5'-untranslated region of a cricket paralysis-like picornavirus. 35. The construct of claim 33, wherein the cistron comprises at least one open reading frame (ORF). 36. The construct of claim 35, wherein the ORF encodes a protein not normally expressed in the host cell. 37. The construct of claim 36, wherein the protein is expressed in the host cell in vitro or in vivo. 38. The construct of claim 36, wherein the protein is antimicrobial or antiviral. 39. A non-naturally-occurring nucleic acid construct for expressing at least one cistron in a host cell, the construct comprising a virus promoter and an insect picornavirus (IPV) internal ribosome entry site (IRES), wherein the promoter and the IRES are operably linked with the cistron for expression of the cistron in the host cell, wherein the promoter is selected from the group consisting of p2 and p61 of infectious hypodermal and hematopoietic necrosis virus (IHHNV). 40. The construct of claim 39, wherein the host cell is selected from a group consisting of bacteria cell, yeast cell, insect cell, fish cell, shellfish cell, and animal cell.

Details for Patent 7,973,148

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26